First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
By LabMedica International staff writers Posted on 18 Mar 2025 |

Every cell in the human body is engaged in constant communication with its environment and operates within a broader network of interactions. Each cell has specific features that help identify it as part of its network, such as the proteins expressed on its surface. These features allow similar cells to be connected based on their characteristics. Advances in single-cell and spatial genomic technologies have greatly enhanced our understanding of the human body, leading to the creation of comprehensive cell atlases that map different tissues and organs. These atlases provide valuable information on various cell types, their locations, and how genetic variations affect their interactions. By understanding the cellular mechanisms of the human body, researchers can gain insights into diseases and identify potential drug development targets. While these atlases offer detailed information about the locations of cells and how they interact within their specific microenvironments, quantifying and interpreting these cellular neighborhoods, as well as understanding the driving forces behind their social interactions, remains a challenge. Now, an innovative AI-based tool is available to interpret millions of human tissue cells in just hours, offering new insights and enabling researchers and clinicians to explore conditions like cancer.
This first-of-its-kind AI-based neural network created by researchers from the Wellcome Sanger Institute (Cambridgeshire, UK) and their collaborators can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue. It holds the potential to identify where personalized treatments might be most effective for conditions like cancer. The groundbreaking tool, called NicheCompass, was introduced in a paper published in Nature Genetics and utilizes generative AI to create a visual database that integrates spatial genomic data on cell types, their locations, and their interactions. This is part of the broader Human Cell Atlas Initiative. NicheCompass is the first AI-based method capable of quantifying and interpreting a range of data, from cell-to-cell communication to identifying and analyzing different cellular neighborhoods.
NicheCompass operates on a deep-learning AI model based on cell-to-cell communication. It learns how cells communicate within their networks and then categorizes these interactions, grouping cells into neighborhoods within tissues based on shared features. This allows NicheCompass to interpret the data, enabling researchers and clinicians to ask critical questions and gain a deeper understanding of health conditions. For instance, NicheCompass has been used to uncover tissue changes in patients with breast and lung cancer. Ultimately, the AI tool will facilitate the development of personalized treatment plans, pinpointing specific molecular alterations that could be targeted in cancer therapies. Researchers have demonstrated that NicheCompass can identify how different individuals may respond to treatments—within just one hour—using the power of AI. In a study, data from 10 lung cancer patients was analyzed, and similarities and differences between the patients were revealed.
These similarities enhance the general understanding of cancer and highlight transcriptional changes that could inform the development of new treatments. On the other hand, the differences point to new potential avenues for personalized therapies. As more patient data becomes available, clinicians will be able to input their patient’s data into NicheCompass and receive a detailed analysis within an hour, aiding clinical decision-making. The team also applied NicheCompass to breast cancer tissue, showing that it can be used effectively across different types of cancer. In another experiment, NicheCompass was used on a spatial atlas of a mouse brain containing 8.4 million cells, successfully identifying brain regions and generating a visual map of the entire organ. This illustrates the tool’s potential to analyze spatial atlases of entire organs, a resource being developed by researchers globally.
“Having a huge amount of data about the human body is crucial to finding new ways to understand, prevent and treat disease,” said Sebastian Birk, first author at the Institute of AI for Health, Helmholtz Munich and the Wellcome Sanger Institute. “However, we also need tools that allow us to access all the benefits this information could provide. NicheCompass is a significant leap in this field, leveraging the power of AI but also offering interpretability, allowing researchers and clinicians to ask questions about their data and better understand and treat diseases.”
Related Links:
Wellcome Sanger Institute
Latest Pathology News
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- New Test Diagnoses High-Risk Childhood Brain Tumors
- Informatics Solution Elevates Laboratory Efficiency and Patient Care
- Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Channels
Clinical Chemistry
view channel
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read moreMolecular Diagnostics
view channel
Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy
Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more